Home GCC Bahrain Bahrain approves China’s Sinopharm Covid-19 vaccine The UAE registered the Sinopharm vaccine after finding it had a 86 per cent efficacy rate by Bloomberg December 13, 2020 Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine. “Results from Phase III clinical trials showed an 86 per cent efficacy rate, a 99 per cent seroconversion rate of neutralising antibody and 100 per cent effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement on Sunday. Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorised the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients. Read: Bahrain approves Covid-19 vaccine for frontline workers The UAE registered the Sinopharm vaccine after finding it had a 86 per cent efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy. Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine. Tags Bahrain Phase III Trials Sinopharm UAE Vaccine Volunteers 0 Comments You might also like Four reasons why investing is for everyone Citigroup to exit retail banking in 13 markets, including Bahrain Abu Dhabi issues first district cooling licence to Saadiyat Cooling UAE’s 100 Million Meals campaign reaches 78% of target in first week